医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Jinchi Biotech’s Giant Salamander Glycopeptides Research Paper Published in ‘Chinese Medical Cosmetology’

2014年10月13日 PM04:00
このエントリーをはてなブックマークに追加


 

ZHANGJIAJIE, China

Jinchi Biotech Ltd. announced that ‘The Giant Salamander Glycopeptides in Resisting Skin Photo-aging Clinical Research’ has been published in ‘Chinese Medical Cosmetology’ Periodical (Volume 4, Issue 3, 2014).

Since 2012, Jinchi Biotech Ltd. has completed 40 cases of clinical observations and research on ‘Giant Salamander Glycopeptides (ADGPs) in resisting skin photo-aging’ with Aesthetic & Laser Plastic Surgery Center of PLA Air Force General Hospital (Professor: Xiaozhong Zhao, Ning Wei, Liangzhen Zhang) and Changsha Yahan Medical Beauty Hospital (Professor: Min Zhou, Jun Guo, Yangli Luo). The research results had proved that ADGPs can be applied to cosmetic and skincare products.

ABOUT JINCHI

www.jc-biotech.com

Owning the world’s only Giant Salamander Museum, Jinchi Biotech Ltd. mainly specialized in the R&D of giant salamander related biotech products with more than 40 skincare and health products under two product lines, namely SHINIQUE and ANDRIAS. With strong scientific research background and a comprehensive business model, Jinchi Biotech Ltd. values virtue and goodwill, commits to deliver quality products to consumers, and devotes to the health, beauty and biomedical industries.

Disclaimer

The statements contained herein are forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those expressed in the forward-looking statements.

CONTACT

Jinchi Biotech Ltd.
Chan Luo, +86-731-8979-2661
ir@jc-biotech.com

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • スミス・ディテクションのBioFlashが空中のCOVID-19を検出可能であることを実証
  • Korean Pet Care Robot PEDDY Gains Popularity to Relieve Pets’ Depression During COVID-19
  • コロナ禍で生じたうつ病をいやす韓国産ペットケアロボット「ペディ」が人気
  • Dr. Reddy’s Laboratories announces the launch of Fluphenazine Hydrochloride Tablets, USP in the U.S. Market
  • Boston Immune Technologies and Therapeutics and BeiGene Enter into an Exclusive Option and License Agreement to Develop Novel TNFR2 Antagonists